Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Data Presented at the 2023 American Society for Bone and Mineral Research Annual MeetingBELTSVILLE, Md., Oct. 17, 2023 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to...

Related Keywords

United States ,Hospital For Special Surgery ,New York ,American ,Timothy Mayer ,Cathleen Raggio ,Exchange Commission ,Mineral Research ,Nasdaq ,Pamerican Society For Bone ,Nextcure Inc ,Data Presented ,Transform Infrared ,Solomon Langermann ,Special Surgery ,Sexual Dimorphism ,Treatment Effect ,Adult Mice ,Moderate To Severe Osteogenesis ,Markets ,